[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@seahorse_anton Dr Anton_Invests

Dr Anton_Invests posts on X about $rr, strong, richtech robotics, $tsla the most. They currently have XX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

X Week XXXXX -XX%

Mentions: XX #

X Week XX no change

Followers: XX #

X Week XX +24%

CreatorRank: XXXXXXXXX #

Social Influence

Social category influence stocks XXXXX% finance XXXXX% cryptocurrencies XXXXX% automotive brands XXXX% currencies XXXX% countries XXXX% travel destinations XXXX% technology brands XXXX%

Social topic influence $rr #6, strong 12.5%, richtech robotics #8, $tsla #327, $rxrx 6.94%, $mrna #18, flow 6.94%, bullish #1466, momentum #1295, target XXXX%

Top accounts mentioned or mentioned by @ckcryptoklepto @syndrome22q1 @catturd2 @gunthereagleman @karolineleavitt @atensnut @lindayax @dbongino @bennyjohnson @alphafox @mrbeast @kmisglobal

Top assets mentioned retard to retired (R/R) Richtech Robotics Inc. Class B Common Stock (RR) Tesla, Inc. (TSLA) Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Moderna Inc (MRNA) Oscar Health, Inc. (OSCR) NVIDIA Corp. (NVDA) ZetaChain (ZETA) CoreWeave, Inc. (CRWV) DLocal Limited Class A Common Shares (DLO) Snap, Inc. (SNAP) Bit Digital, Inc. (BTBT) AstraZeneca PLC (AZN) Regeneron Pharmaceuticals Inc (REGN)

Top Social Posts

Top posts by engagements in the last XX hours

"1. History AbCellera Biologics Inc. $ABCL Founded in 2012 in Vancouver British Columbia Canada. The company was spun out of academic research at University of British Columbia (UBC). The founder Dr. Carl Hansen was a UBC faculty member. Founding team includes Carl Hansen Vronique Lecault Kevin Heyries Daniel Da Costa and others. Early technology: built around microfluidics single-cell analysis next-gen sequencing AI/ML applied to antibody discovery. Headquarters: Vancouver Canada. Recursion Pharmaceuticals Inc. $RXRX Founded in 2013 in the United States (originally based in Salt Lake City"
X Link 2025-11-19T19:02Z XX followers, XXX engagements

"6) The SHORT Warning $RXRX The Hybrid Keltner System has a current SHORT bias at XXXX USD. SHORT Target: XXXX USD. SL: XXXX USD. This is a tactical signal against the macro trend. The high XXXX R/R suggests this short may fail but the Keltner signal is valid for breakdown entries"
X Link 2025-12-05T20:03Z XX followers, XXX engagements

"This deep dive provides a detailed look into the history structure and early financing of Moderna Inc. $MRNA Pre-IPO Funding The company was a fundraising machine well before its public debut which contributed to its high initial valuation. Total Venture Capital: Between 2011 and 2017 Moderna raised over $X billion in venture capital funding. Total Funding (Pre-IPO): By September 2018 the company had raised over $XXX billion in total funding from strategic collaborators and investors. Cash Generation: Free Cash Flow followed a similar trajectory jumping to 13.336$ billion in 2021 and"
X Link 2025-12-10T18:51Z XX followers, XX engagements

"My Take $OSCR Daily ML probability is weak (17%) and the 4H score is strongly bearish (-45). Volume flow (CMF + VPT) is negative on both timeframes confirming distribution not accumulation. No bullish setup here momentum needs to flip before any long entry makes sense. 🤖 Breakout Prediction for OSCR (Daily) Close: $XXXXX Support: $XXXXX Resistance: $XXXXX RSI: XXXX MACD: -XXXX OBV Z-Score: XXX (Neutral) Breakout Up Probability (5 days ML): XX% 🟢 Cloud: Neutral Trend: Neutral (This is the only advantage here) Volume Note (OBV + VPT + CMF): OBV Z is neutral no strong accumulation CMF negative"
X Link 2025-12-11T20:31Z XX followers, XXX engagements

"Upcoming Thread: Richtech Robotics $RR Fundamentals to Stock Structure"
X Link 2025-12-12T20:59Z XX followers, XXX engagements

"🧵THE ROBOTS ARE REVOLTING RichTech Robotics 🤖 $RR From Fundamentals to Stock Structure 🤖 Richtech Robotics (RR) Competitive Advantages: The core advantage of RR is centered on making robotics accessible and practical for the service industry which is experiencing severe labor shortages. X. The RaaS Model (Robotics-as-a-Service) This is the most critical strategic differentiator and the reason for the high stock valuation despite current losses. Low Barrier to Entry for Customers: Traditional robotics required huge upfront Capital Expenditures (CapEx). RR's pivot to a RaaS model shifts the"
X Link 2025-12-12T21:39Z XX followers, XXX engagements

"2. Product Focus & Practical AI $RR Unlike companies focused on complex humanoid robots or deep industrial automation RR targets the service industry with highly practical task-specific robots. Focus on 'Dull Dirty and Dangerous' Tasks: RR's robots are purpose-built to automate mundane logistics in hospitality healthcare and retail (e.g. delivery cleaning drink service). This directly addresses the labor shortage crisis. Examples: Matradee Plus (Food Runner) Medbot (Medical Delivery) Scorpion (AI Bartender). "Physical AI" That Works: RR emphasizes delivering "real-world ROI" over "AI hype.""
X Link 2025-12-12T21:39Z XX followers, XX engagements

"3. Strategic Technology & Manufacturing Advantages $RR NVIDIA Partnership: RR partners with NVIDIA $NVDA integrating platforms like NVIDIA Jetson (for edge computing) and Isaac Sim (for simulation). This gives them access to top-tier AI hardware and accelerates their development and deployment timeline. "Made in America" Strategy: Conducting parts of their manufacturing and R&D process in the US allows for real-time iteration based on customer feedback and provides protection from volatile global supply chains which can be a key vulnerability for robotics companies. Diverse Product Portfolio:"
X Link 2025-12-12T21:39Z XX followers, XXX engagements

"$RR is essentially a highly speculative bet on the RaaS model successfully scaling to capitalize on the practical AI/robotics boom using the cash raised from dilution to fund the growth until profitability is achieved"
X Link 2025-12-12T21:39Z XX followers, XXX engagements

"Let's summarize again $RR Dilution Takeaway Pressure on EPS: The growing share count means future earnings must grow at an even faster rate just to keep Earnings Per Share (EPS) from fallingmaking the fundamental justification for rallies harder. Cap on Rallies: The ATM program suggests management may view price spikes as an opportunity to raise more capital. Look for TA resistance at levels that coincide with major or recent ATM announcements. Volume Significance: Any significant upward movement must be backed by exceptionally high volume to confirm that market demand is truly absorbing the"
X Link 2025-12-12T21:39Z XX followers, XXX engagements

"📊 Verified Balance Sheet (June XX 2025) $RR From the companys unaudited Form 10-Q filed with the SEC: Current Assets (most recent quarter): Cash and cash equivalents: $32893 K (about $XXXX M) SEC Short-term investments: $52616 K (about $XXXX M) SEC Accounts receivable (net): $1694 K (about $XXX M) SEC ➡ Cash + Short-Term Investments (Liquid Assets): $XXXX M this is where figures like $XX M cash reserve come from (cash + marketable securities) but the raw cash and equivalents line in SEC is $XXXX M. Liabilities & Equity: Current liabilities: $XXXX M (very low) Long-term debt: $XXXX M (also"
X Link 2025-12-12T21:39Z XX followers, XXX engagements

"CONCLUSION The investment thesis for Richtech Robotics $RR is one of pure paradox demanding conviction in future technology. On one side the company possesses visionary potential: a high-margin (76% Gross Margin) RaaS-driven solution that directly addresses the acute labor shortages in the service industry. The global RaaS market itself is projected to see a CAGR of XX% through 2035 providing a massive tailwind for RR's strategy to build a recurring revenue model and scale its operations. On the other side the operational cost of chasing this vision is steep: the company is aggressively"
X Link 2025-12-12T21:39Z XX followers, XXX engagements

"🧵TESLA $TSLA TRAP: Why the +0.07 Neutral Signal Masks a $XXX Breakout 1/7 The Hook: Structural Bull Quant Neutral Visually TSLA printed a strong continuation candle reclaiming momentum levels. Structurally bullish. BUT our Weekly Quant Model flags a Neutral Trap. The next move is major but requires patience"
X Link 2025-12-12T23:07Z XX followers, XX engagements

"🧵🙇♂ Deep Dive $ABCL (AbCellera) vs $RXRX (Recursion) - Biotechs Data War Antibodies vs Algorithms The Diverging Roads of AI-Driven Biotech In the new era where biology meets computation two companies stand at the crossroads of innovation AbCellera (ABCL) and Recursion Pharmaceuticals (RXRX). Both were born from the same scientific ambition: to industrialize drug discovery using data automation and machine intelligence. Yet their paths could not be more different. AbCellera has mastered the art of antibody discovery combining microfluidics and machine learning to find therapeutic needles in"
X Link 2025-11-19T19:00Z XX followers, 3295 engagements

"My Take: $TIGR is pushing above resistance around the Q3 report with ML showing a bullish XX% breakout probability but the daily cloud is still not sure meaning structure hasnt turned yet. 4H shows a strong XX confirmation score boosted by a volatility-hole signal but VPT divergence warns of weak volume support. Overall High short-term momentum but cloud + volume divergence = not clean breakout yet. Trying to push further. (D) Daily Breakout Forecast Close: $XXXX Support: $XXXX Resistance: $XXXX RSI: XXXX MACD: XXXX histogram +0.04 (bullish inflection) OBV Z-Score: XXX Neutral flow ML"
X Link 2025-12-04T20:19Z XX followers, XXX engagements

"UP Fintech $TIGR reported record-high revenue and profit for Q3 2025 driven by strong growth in its international markets like Singapore and Hong Kong. Key Financial Highlights: Total Revenue: US$175.2 million a XXXX% increase year-over-year (YoY). Non-GAAP Net Income: US$57.0 million approximately XXX times the level YoY also a record high. Total Client Assets: Hit a new peak of US$61.0 billion up XXXX% YoY. Operational Highlights:Funded Accounts: Added 31500 new funded clients bringing the total to XXXX million (up XXXX% YoY). Annual Target: The company already met its full-year target of"
X Link 2025-12-04T20:20Z XX followers, XXX engagements

"$CRWV broke above resistance but daily cloud suggests sth. Trending towards neutral and the ML model only gives XX% breakout probability firmly in the possible but weak category. 4H momentum is strong - improving (MACD strong RSI elevated) but with a neutral cloud + Doji + VPT divergence the upside still lacks confirmation. Overall Mixed setup strong short-term buying pressure but higher-timeframe trend still not aligned. Guys who bought at XX are great. I missed (D) Daily Close: $XXXXX Support: $XXXXX Resistance: $XXXXX RSI: XXXX (neutral) MACD: XXXX bullish histogram (+2.90) OBV Z-Score:"
X Link 2025-12-05T16:54Z XX followers, XXX engagements

"Daily & 4H: The Groundwork $RXRX The lower timeframes show the base-building is underway: Daily: ML Breakout UP is low (31%). Cloud remains Bearish. 4H: Confirmation Score is XX (Neutral). CMF is strong (0.180) showing institutional inflows. Conclusion: The stock has stopped breaking down but it is not yet trending up"
X Link 2025-12-05T20:03Z XX followers, XXX engagements

"The Levels: Defining the Trade The model gives a clean structure for when the inevitable flip occurs: Target (Upside R/R): XXXX USD. Stop-Loss (Downside Cap): XXXX USD. Trend Pivot: $RXRX must reclaim the Kijun at XXXX USD to turn momentum neutral"
X Link 2025-12-05T20:03Z XX followers, XXX engagements

"7) Final Takeaway $RXRX is entering the accumulation-compression phase. Risk is now asymmetric to the upside. The signal is NEUTRAL but the structural improvement is massive. Watch for a clean close above XXXX USD for the long trigger"
X Link 2025-12-05T20:03Z XX followers, XXX engagements

"This week simplified update 📉📈 Started adding $DLO again at XXXXX will DCA from here. Added $SNAP at XXXX. Added to my $NVDA position. Lowered my $BTBT DCA to below X. Still holding $RR (DCA 3.30). Not selling anything in robotics right now even though selling would boost my yearly performance. Im not here to chase rankings. Funny how the more I analyze compare review charts and think things through the fewer trades I make but with much higher conviction. Hope I helped some along the way 🙏"
X Link 2025-12-05T20:55Z XX followers, XXX engagements

"Quant + Momentum Breakdown: $TTR Weekly Quant View Strong Bearish Our TBM/HAC model prints XXXX with a bearish regime and weak R/R (0.6). MACD RSI OBV Z-score and volume internals all confirm momentum decay + distribution. Chikou spans below price/cloud trend intact. Neutral drift dominates but downside volatility is still expanding"
X Link 2025-12-07T11:57Z XX followers, XXX engagements

"Risk Levels + Whats Next: $TTR Key Levels & Risk Map Support: $3840 then $XX $XXXXX. Reversal requires: reclaiming $XX (Tenkan) $XX (Kijun). Below $XX Opens a fresh leg lower. Hybrid system still shows bearish macro trend + short-biased precision triggers. Bottom line: structure first sentiment later. Trend hasnt turned"
X Link 2025-12-07T11:57Z XX followers, XX engagements

"I ran simulations on Richtech Robotics $RR This is not like $ZETA or $OSCR where XX models tightly cluster. Here all upside-leaning forecasts come with catastrophic drawdowns: VaR losses 8096% Extreme volatility regime LSTM refusing to confirm trend Translation: Upside is possible but risk profile is explosive and asymmetric. 💡 My Take This is a high-variance lottery ticket not a trend-backed momentum setup. When ensembles split this far apart it signals uncontrolled volatility + weak signal reliability. If trading: Stop-loss: $XXXX (protect capital) Expect violent swings and unreliable"
X Link 2025-12-07T20:00Z XX followers, XX engagements

"3. 💉Research Pipeline and Clinical Focus: Phase X X and X $MRNA Modernas pipeline is divided into four strategic areas: Seasonal Vaccines Latent & Other Vaccines Oncology and Rare Disease Therapeutics. The strategy is currently focused on leveraging the cash generated from approved products to aggressively fund the development of its non-COVID portfolio. Phase X & Approved Programs Modernas late-stage pipeline is characterized by multiple respiratory vaccines aiming to build a large commercial franchise"
X Link 2025-12-10T18:51Z XX followers, XX engagements

"Phase X Programs $MRNA These assets represent the mid-stage programs that will drive diversification beyond respiratory viruses"
X Link 2025-12-10T18:51Z XX followers, XX engagements

"🤝 Key Partnerships and Collaborations $MRNA Moderna strategically relies on collaborations to share R&D risk gain access to specialized technology and leverage commercial expertise outside of its core focus. $MERCK $VERTEX"
X Link 2025-12-10T18:51Z XX followers, XX engagements

"Key Competitors BioNTech / Pfizer Comparable mRNA capabilities; strong LNP technology. CureVac & Acuitas (Note: Curevac is now acquired by BionTech) Developing alternative mRNA and LNP systems. Regeneron $REGN Merck AstraZeneca $AZN Scaling biologics platforms that may compete indirectly by alternative modalities. Why this matters: Manufacturing scalability + cost of goods will determine long-term margins. mRNA vaccines must beat protein/subunit vaccines on economics not just speed. Moderna competes against world-class incumbents in every category vaccine giants in respiratory disease"
X Link 2025-12-10T18:51Z XX followers, XXX engagements

"5. 💰 IPO & Fundamentals (Including Q3 2025 Report) $MRNA Modernas Initial Public Offering (IPO) in late 2018 was historic for the biotechnology sector demonstrating strong investor confidence in the unproven mRNA platform"
X Link 2025-12-10T18:51Z XX followers, XX engagements

"Let's see the high-growth unprofitable company like Richtech Robotics $RR . The relationship between these metrics shows the challenge of their RaaS pivot and their reliance on capital raises (dilution). Here is the comparison between Total Revenue Net Income and Free Cash Flow (FCF) focusing on the most recent available quarters (Q1-Q3 2025): Total Revenue vs. Net Income Richtech Robotics is experiencing a significant operational challenge where its expenses vastly outweigh its sales resulting in deep net losses despite having a top-line. The Problem: The company operates with a massively"
X Link 2025-12-12T21:39Z XX followers, XX engagements

"Overall Richtech Robotics $RR shows a clear deterioration in financial performance over the reported period. Revenues declined from $6M in Sep XX to $4.1M LTM representing a XXXX% total change and a negative CAGR of 13%. At the same time profitability moved sharply in the wrong direction: net income went from modest losses ($0.5M) to significantly deeper losses ($15.1M LTM). Despite a brief revenue uptick in Sep XX the company failed to convert sales into earnings and operating leverage appears negative. The widening gap between shrinking revenue and accelerating net losses signals cost"
X Link 2025-12-12T21:39Z XX followers, XX engagements

"Net Income vs. Free Cash Flow $RR The comparison between Net Income (an accounting measure of profitability) and Free Cash Flow (the actual cash generated or burned) highlights the rate at which the company is consuming capital"
X Link 2025-12-12T21:39Z XX followers, XX engagements

"The following chart highlights an even more concerning trend: cash generation is deteriorating faster than accounting profitability. Net losses expanded from $0.5M to $15.1M LTM while free cash flow dropped from $2.6M to $19.4M LTM a massive deterioration despite what appears as an initially improving FCF trend measured by total change calculations. The divergence underscores rising operating cash burn and potentially increasing working-capital strain. When both net income and free cash flow are deeply negative and getting worse it suggests that the company is funding operations through"
X Link 2025-12-12T21:39Z XX followers, XX engagements

"Current Shares Outstanding for Richtech Robotics $RR The latest complete breakdown of shares outstanding is from the Q3 2025 period (ending June XX 2025) and subsequent updates regarding their dilution program. X. Shares Outstanding (The Official Breakdown) The most detailed number is an update from August XX 2025 which provides the breakdown after significant ATM (At-The-Market) share issuances:"
X Link 2025-12-12T21:39Z XX followers, XX engagements

"2. The Dilution Impact (The Fundamental Focus) $RR The key takeaway is the speed of dilution which has accelerated significantly in the last year: Massive Recent Increase: In the four months between March XX 2025 and August XX 2025 the number of Class B shares outstanding grew from approximately $71.5$ million to nearly $110$ million (an increase of 38.5$ million shares). The ATM Program: This growth is driven by the use of the At-The-Market (ATM) offering which allows the company to continuously issue new shares directly into the market to raise cash. Fundamental Headwind: This continuous"
X Link 2025-12-12T21:39Z XX followers, XX engagements

"2/7 The Quant Verdict: Coiling $TSLA The TBM/HAC model detects no directional edge this weekit sees a coiling phase:Neutral Probability: An overwhelming XXXX % chance of sideways action immediately. R/R: Probability-Weighted R/R is 0.71X. Trading now is unattractive. Drivers: RSI CMF Tenkan and Kijun are all flattening. This is a classic high-compression low-conviction environment"
X Link 2025-12-12T23:07Z XX followers, XX engagements

"3/7 The Long-Term Forecast: The Magnet $TSLA Despite the short-term pause the long-term price target is overwhelmingly bullish fueled by AI and Energy. Ensemble Target (3 months): 545.78$ (Bayesian Average). Probability of Positive Return: XXXX %. Analyst Median Target: 453$ with high targets at 600$. The compression is not trend failureits loading for the next leg up "
X Link 2025-12-12T23:07Z XX followers, XX engagements

"4/7 The Technical Buy Zone $TSLA TSLA held up well during recent volatility a constructive sign. The technical levels are clear:Momentum Support (Tenkan): 457.5$ must hold to maintain the immediate bullish control. Major Trend Support (Kijun): 428.4$ the floor for the correction"
X Link 2025-12-12T23:07Z XX followers, XX engagements

"5/7 The Breakout Trigger $TSLA The Daily chart shows strong internal support even during the pause:Daily Volume Z-Score is 1.9Bullish volume flow. Breakout Probability ML: XXXX% chance of moving up in X days. Breakout Level: A decisive push through 460$ would mark a textbook breakout"
X Link 2025-12-12T23:07Z XX followers, XX engagements

"6/7 The Strategy: Wait for the Break $TSLA The Keltner System fired a BUY signal at 440.40$ but the Weekly Neutral bias demands caution. Action: SIT OUT until the XXXX% Neutral zone clears. Long Entry Trigger: Weekly close above XXX - 480$ (Overhead Supply). Target: XXXXXX Weekly Quant ATR ---545$ Ensemble"
X Link 2025-12-12T23:07Z XX followers, XX engagements

"7/7 Final Takeaway $TSLA is coiling for a major expansion . The direction is likely up but attempting to trade the XXXX% sideways range is futile. Buy Trigger: Breakout above XXX. Stop: Loss of XXXXX $ Kijun. The next move is significant. Be patient. Do Your Own Research. No Investment Advice"
X Link 2025-12-12T23:07Z XX followers, XXX engagements